Fractyl Health, Inc. (GUTS)
NASDAQ: GUTS · Real-Time Price · USD
1.010
-0.860 (-45.99%)
At close: Aug 6, 2025, 4:00 PM
0.9899
-0.0200 (-1.99%)
After-hours: Aug 6, 2025, 7:08 PM EDT
Perficient Revenue
Fractyl Health had revenue of $60.00K in the twelve months ending March 31, 2025, down -59.46% year-over-year. In the year 2024, Fractyl Health had annual revenue of $93.00K, down -22.50%.
Revenue (ttm)
$60.00K
Revenue Growth
-59.46%
P/S Ratio
1,526.44
Revenue / Employee
$561
Employees
107
Market Cap
49.47M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 93.00K | -27.00K | -22.50% |
Dec 31, 2023 | 120.00K | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
GUTS News
- 3 hours ago - Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference - GlobeNewsWire
- 10 hours ago - Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering - GlobeNewsWire
- 1 day ago - Fractyl Health Announces Proposed Public Offering - GlobeNewsWire
- 1 day ago - Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita® Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure - GlobeNewsWire
- 21 days ago - Fractyl Health: Speculative Buy With Binary Risk - Seeking Alpha
- 6 weeks ago - Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy - GlobeNewsWire
- 6 weeks ago - Fractyl Health Presents New Data at the American Diabetes Association's 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models - GlobeNewsWire
- 7 weeks ago - Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing - GlobeNewsWire